

(19) World Intellectual Property Organization
International Bureau(43) International Publication Date
28 November 2002 (28.11.2002)

PCT

(10) International Publication Number
WO 02/094203 A2(51) International Patent Classification⁷: **A61K**

(21) International Application Number: PCT/US02/16963

(22) International Filing Date: 24 May 2002 (24.05.2002)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/293,642 24 May 2001 (24.05.2001) US(71) Applicant (for all designated States except US): **AVANIR PHARMACEUTICALS** [US/US]; 11388 Sorrento Valley Road, Suite 200, San Diego, CA 92121 (US).

(72) Inventors; and



(75) Inventors/Applicants (for US only): **GAETA, Federico, C.A.** [US/US]; 137 Laurel Way, Mountain View, CA 94040 (US). **BAIRD, Andrew** [US/US]; 1834 Torrance Street,San Diego, CA 92103 (US). **ANCHIN, Jerry** [US/US]; 216 King Street, Apt. C, Charleston, SC (US). **YING, Wenbin** [US/US]; 7478 Park Village Road, San Diego, CA 92129 (US). **FLORKIEWICZ, Robert** [US/US]; 126 - North West 40th Street, Seattle, WA 98107 (US). **SIR-CAR, Jagadish** [US/US]; 4832 Riding Ridhe Road, San Diego, CA 92130 (US). **KUMAR K.C., Sunil** [NP/US]; 8155 Cargill Avenue, Apt. 30, San Diego, CA 92122 (US).(74) Agent: **ALTMAN, Daniel, E.**; Knobbe, Martens, Olson & Bear, LLP, 620 Newport Center Drive, 16th Floor, Newport Beach, CA 92660 (US).

(81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ (utility model), CZ, DE (utility model), DE, DK (utility model), DK, DM, DZ, EC, EE (utility model), EE, ES, FI (utility model), FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM,


[Continued on next page]

(54) Title: INHIBITORS OF MACROPHAGE MIGRATION INHIBITORY FACTOR AND METHODS FOR IDENTIFYING THE SAME

Mechanism of Action and Detection



(Ia)



(Ib)

(57) Abstract: Inhibitors of MIF are provided which have utility in the treatment of a variety of disorders, including the treatment of pathological conditions associated with MIF activity. The inhibitors of MIF have the following structures: (Ia) (Ib) including stereoisomers, prodrugs and pharmaceutically acceptable salts thereof, wherein n, R₁, R₂, R₃, R₄, X, Y and Z are as defined herein. Compositions containing an inhibitor of MIF in combination with a pharmaceutically acceptable carrier are also provided, as well as methods for use of the same.



PH, PL, PT, RO, RU, SD, SE, SG, SI, SK (utility model), SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW.

- (84) Designated States (regional):** ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Declaration under Rule 4.17:

— *of inventorship (Rule 4.17(iv)) for US only*

Published:

— *without international search report and to be republished upon receipt of that report*

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.